Nicolas Girard, MD

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

Nicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).